Published in
American Society for Microbiology, Antimicrobial Agents and Chemotherapy, 7(65), 2021
DOI: 10.1128/aac.00293-21
Links
Tools
Amikacin Combined with Fosfomycin for Treatment of Neonatal Sepsis in the Setting of Highly Prevalent Antimicrobial Resistance
Journal article published in 2021 by
Christopher A. Darlow 
,
Fernando Docobo-Perez,
Nicola Farrington,
Adam Johnson,
Laura McEntee,
Jennifer Unsworth,
Ana Jimenez-Valverde,
Silke Gastine ,
Ruwanthi Kolamunnage-Dona,
Renata M. A. de Costa,
Sally Ellis,
François Franceschi,
Joseph F. Standing,
Mike Sharland,
Michael Neely
and other authors.
,
Fernando Docobo-Perez,
Nicola Farrington,
Adam Johnson,
Laura McEntee,
Jennifer Unsworth,
Ana Jimenez-Valverde,
Silke Gastine ,
Ruwanthi Kolamunnage-Dona,
Renata M. A. de Costa,
Sally Ellis,
François Franceschi,
Joseph F. Standing,
Mike Sharland,
Michael Neely
and other authors.
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Data provided by 
Abstract
Antimicrobial resistance (particularly through extended-spectrum β-lactamase and aminoglycoside-modifying enzyme production) in neonatal sepsis is a global problem, particularly in low- and middle-income countries, with significant mortality rates. High rates of resistance are reported for the current WHO-recommended first-line antibiotic regimen for neonatal sepsis, i.e., ampicillin and gentamicin.